PHAT - Phathom Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$24.67
DETAILS
HIGH:
$28.00
LOW:
$18.00
MEDIAN:
$28.00
CONSENSUS:
$24.67
UPSIDE:
117.74%
About Phathom Pharmaceuticals, Inc. (https://www.phathompharma.com)
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Azmi Nabulsi | Co-Founder | 1960 | $1,950,012 USD |
| David A. Socks | Co-Founder | 1975 | $1,950,012 USD |
| Steven L. Basta | Chief Executive Officer, President & Director | 1966 | $1,173,151 USD |
| Anne Marie Cook | Chief Legal Officer & Corporate Secretary | 1962 | $663,406 USD |
| Sanjeev Narula | Chief Financial & Business Officer | 1962 | $644,285 USD |
| Bill Aprea | Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer | – | – |
| Eckhard Leifke | Chief Medical Officer | – | – |
| Eric Sciorilli | Director of Business Development & Investor Relations | – | – |
| Jay Buchanan | Senior VP of Manufacturing & Supply Chain | – | – |
| Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training | – | – |
| Nancy R. Phelan | Senior Vice President of Marketing & Analytics | 1969 | – |
| Paul Cocja | Chief People Officer | – | – |
| Robert Breedlove | Vice President of Finance & Principal Accounting Officer | – | – |